Pre-treatment pan-immune-inflammation value as a prognostic marker of pazopanib in soft tissue sarcoma

被引:0
|
作者
Wu, Cheng-Han [1 ,3 ]
Lai, Cheng-Lun [1 ]
Hsu, Yong-Chen [4 ]
Hsu, Chiann-Yi [5 ]
Wang, Yu-Chao [3 ]
Lin, Hsin-Chen [1 ,2 ]
机构
[1] Taichung Vet Gen Hosp, Dept Oncol, Div Med Oncol, Taichung 407219, Taiwan
[2] Natl Chung Hsing Univ, Coll Med, Dept Postbaccalaureate Med, Taichung 402202, Taiwan
[3] Natl Yang Ming Chiao Tung Univ, Inst Biomed Informat, Taipei, Taiwan
[4] Taichung Vet Gen Hosp, Dept Pathol, Taichung, Taiwan
[5] Taichung Vet Gen Hosp, Biostat Task Force, Taichung, Taiwan
关键词
pan-immune-inflammation value; pazopanib; sarcoma; RATIO;
D O I
10.1177/17588359241292255
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Increasingly, more evidence has shown that inflammation stress and the tumor microenvironment pose a negative effect on targeted therapy. The neutrophil-to-lymphocyte ratio is considered to be a surrogate biomarker of inflammation and can predict pazopanib treatment effect in non-adipocytic soft-tissue sarcoma (STS). The role of the pan-immune-inflammation value (PIV) in STS is still yet to be determined. Objectives: We sought whether the pre-treatment PIV could be applied to predict the response of pazopanib in STS. Design: We conducted a retrospective analysis of 75 patients who had been treated with pazopanib for recurrent or metastatic non-adipocytic STS. Methods: Our cohort was stratified into either a pre-treatment high PIV group with PIV >= 310 (n = 45) or a low PIV group with PIV <310 (n = 30). We compared their clinical features and outcomes. Cox regression analysis was employed to determine the risk factors of disease progression and mortality. Kaplan-Meier survival curves were utilized to assess both the progression-free survival (PFS) and overall survival (OS). Results: The results revealed that a pre-treatment high PIV (>= 310) is a risk factor for progression under pazopanib (hazard ratio: 1.91; 95% confidence interval: 1.08-3.36; p = 0.025). The median PFS and OS of the pre-treatment high PIV group were found to be significantly lower than the low PIV group (0.33 vs 0.75 years; p = 0.023, 0.46 vs 1.63 years; p = 0.025). Conclusion: High pre-treatment PIV in STS patients may indicate an elevated risk of disease progression and mortality. Pre-treatment PIV reflects inflammation stress and acts as a practical biomarker for STS patients treated with pazopanib.
引用
收藏
页数:12
相关论文
共 50 条
  • [41] Pazopanib for the treatment of metastatic nonadipocytic soft-tissue sarcoma.
    Aydin, Fazil
    Topcu, Turkan Ozturk
    Ozdemir, Feyyaz
    Sahin, Nazim Onur
    Kavgaci, Halil
    Kandaz, Mustafa
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [42] Worth of pan-immune-inflammation value in trismus prediction after concurrent chemoradiotherapy for nasopharyngeal carcinomas
    Somay, Efsun
    Yilmaz, Busra
    Topkan, Erkan
    Ozdemir, Beyza Sirin
    Ozturk, Duriye
    Besen, Ali Ayberk
    Mertsoylu, Huseyin
    Selek, Ugur
    INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 2024, 39 (01): : 80 - 88
  • [43] The relationship of pan-immune-inflammation value (PIV) and HALP score with prognosis in patients with atrial fibrillation
    Eyiol, Azmi
    MEDICINE, 2024, 103 (36)
  • [44] The Pan-Immune-Inflammation Value in Patients with Metastatic Melanoma Receiving First-Line Therapy
    Giovanni Fucà
    Teresa Beninato
    Marta Bini
    Laura Mazzeo
    Lorenza Di Guardo
    Carolina Cimminiello
    Giovanni Randon
    Giulia Apollonio
    Ilaria Bisogno
    Marta Del Vecchio
    Claudia Lauria Pantano
    Massimo Di Nicola
    Filippo de Braud
    Michele Del Vecchio
    Targeted Oncology, 2021, 16 : 529 - 536
  • [45] Pan-immune-inflammation value predicts immunotherapy response and reflects local antitumor immune response in rectal cancer
    Wang, Qianyu
    Zhong, Wentao
    Xiao, Yi
    Lin, Guole
    Lu, Junyang
    Xu, Lai
    Zhang, Guannan
    Liu, Aijun
    Du, Junfeng
    Wu, Bin
    CANCER SCIENCE, 2024,
  • [46] Prognostic Value of Pre-Treatment F-18 FDG PET/CT Parameters in Soft-Tissue Sarcomas
    Sivrikoz, I. Ak
    Deveci, H.
    Cincin, E.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (SUPPL 1) : S574 - S574
  • [47] Pan-immune-inflammation value independently predicts disease recurrence in patients with Merkel cell carcinoma
    Gambichler, T.
    Said, S.
    Abu Rached, N.
    Scheel, C. H.
    Susok, L.
    Stranzenbach, R.
    Becker, J. C.
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2022, 148 (11) : 3183 - 3189
  • [48] Pan-immune-inflammation value and survival in patients with breast cancer from a Peruvian reference hospital
    Palomino-Secca, Iris
    Pena-Tuya, Mariella
    Quintana-Garcia, Lynn A.
    Guevara Pinares, Miguel A.
    Quinones-Laveriano, Dante M.
    Malpartida Palomino, Robert
    De La Cruz-vargas, Jhony A.
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [49] The association between pan-immune-inflammation value and survival in head and neck squamous cell carcinoma
    Deniz Can Guven
    Enes Erul
    Feride Yilmaz
    Serkan Yasar
    Hasan Cagri Yildirim
    Fatih Ercan
    Yunus Kaygusuz
    Kerim Cayiroz
    Mete Tugcan Ucdal
    Furkan Yesil
    Gozde Yazici
    Mustafa Cengiz
    Ibrahim Gullu
    Sercan Aksoy
    European Archives of Oto-Rhino-Laryngology, 2023, 280 : 2471 - 2478
  • [50] The Role of Pan-Immune-Inflammation Value in Determining the Severity of Coronary Artery Disease in NSTEMI Patients
    Cetinkaya, Zeki
    Kelesoglu, Saban
    Tuncay, Aydin
    Yilmaz, Yucel
    Karaca, Yucel
    Karasu, Mehdi
    Secen, Ozlem
    Cinar, Ahmet
    Harman, Murat
    Sahin, Seyda
    Akin, Yusuf
    Yavcin, Ozkan
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (05)